These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34757213)

  • 1. Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe.
    von Moos R; Lewis K; Massey L; Marongiu A; Rider A; Seesaghur A
    Bone; 2022 Jan; 154():116243. PubMed ID: 34757213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe.
    Body JJ; von Moos R; Rider A; Hallworth P; Bhowmik D; Gatta F; Hechmati G; Qian Y
    J Bone Oncol; 2019 Feb; 14():100212. PubMed ID: 30627511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital.
    Seesaghur A; Egger P; Warden J; Abbasi A; Levick B; Riaz M; McMahon P; Thompson M; Cheeseman S
    BMJ Open; 2023 May; 13(5):e069214. PubMed ID: 37156580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018.
    Nicholson G; Carlson KB; Hernandez RK; Schenfeld J; Cadieux B; Henry D; De Sousa Barbosa VJ; Saad H
    Am J Clin Oncol; 2024 Apr; 47(4):177-184. PubMed ID: 38200688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.
    von Moos R; Body JJ; Rider A; de Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
    J Bone Oncol; 2018 Jun; 11():1-9. PubMed ID: 29892519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany.
    Link H; Diel I; Ohlmann CH; Holtmann L; Kerkmann M;
    Support Care Cancer; 2020 May; 28(5):2175-2184. PubMed ID: 31410600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.
    Butler AM; Cetin K; Hernandez RK; Diane Reams B; Overman RA; I Kim J; Hirsch BR; Abernethy AP; Liede A; Alan Brookhart M
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):229-238. PubMed ID: 29316026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study.
    Jakob A; Zahn MO; Nusch A; Werner T; Schnell R; Frank M; Hamm N; Däßler KU; Losem C; Welslau M; Hoevel P; Potthoff K
    J Bone Oncol; 2022 Apr; 33():100420. PubMed ID: 35340302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States.
    Henry D; von Moos R; Body JJ; Rider A; De Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
    Curr Med Res Opin; 2019 Mar; 35(3):375-381. PubMed ID: 30550358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
    Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
    Phillips WJ; Saad F; Leigh J; Jooya A; Webber C; Morgan S; MacRae R; Bourque JM; Tanuseputro P; Ong M
    Oncologist; 2024 Oct; 29(10):878-886. PubMed ID: 38527096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone-targeting agents in major solid tumour metastases: a multinational cohort study.
    Kim JH; Shen CY; Au PC; Baek YH; Cheung CL; Chung WP; Kleinman NJ; Lam TC; Liao TC; Lin TC; Shin JY; Sing CW; Wong ICK; Lai EC
    BMJ Support Palliat Care; 2024 Jan; 13(e3):e1064-e1073. PubMed ID: 35177433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study.
    Schröder J; Fietz T; Köhler A; Petersen V; Tesch H; Spring L; Fleitz A; Jänicke M; Marschner N;
    Eur J Cancer; 2017 Jul; 79():139-148. PubMed ID: 28494404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.
    Alzahrani M; Stober C; Liu M; Awan A; Ng TL; Pond G; Alshamsan B; Vandermeer L; Clemons M
    Support Care Cancer; 2022 May; 30(5):3977-3984. PubMed ID: 35059864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
    Clemons M; Ong M; Stober C; Ernst S; Booth C; Canil C; Mates M; Robinson A; Blanchette P; Joy AA; Hilton J; Aseyev O; Pond G; Jeong A; Hutton B; Mazzarello S; Vandermeer L; Kushnir I; Fergusson D;
    Eur J Cancer; 2021 Jan; 142():132-140. PubMed ID: 33023785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
    Oster G; Lamerato L; Glass AG; Richert-Boe KE; Lopez A; Chung K; Richhariya A; Dodge T; Wolff GG; Balakumaran A; Edelsberg J
    Support Care Cancer; 2014 May; 22(5):1363-73. PubMed ID: 24389827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.
    Zekri J; Farag K; Yousof O; Zabani Y; Mohamed W; Ahmed GA
    J Oncol Pharm Pract; 2020 Jun; 26(4):906-911. PubMed ID: 31575357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
    Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
    Anton A; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Semira MC; Gibbs P; Tran B; Pezaro C
    Eur J Cancer; 2021 Nov; 157():485-492. PubMed ID: 34344533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
    Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
    Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.